Cardiac Monitoring - Tools, Technology, Tradeoffs, and Trust - Powered by iRhythm-Cardiac Monitoring - Tools, Technology, Tradeoffs, and Trust

Cardiac Monitoring - Tools, Technology, Tradeoffs, and Trust - Powered by iRhythm

Video Transcription

Video Summary

The panel discussed how to best monitor atrial fibrillation (AF) and use monitoring data to guide treatment after ablation. A central theme was that longer monitoring, such as 7–14 days, often detects meaningful AF episodes that 48-hour monitoring can miss, with one data set suggesting 30% of first AF episodes would be missed in the first two days alone. The group agreed that monitoring strategy should depend on the clinical question: anticoagulation, symptom assessment, recurrence detection, or burden estimation.<br /><br />They also emphasized that AF burden matters, but only when measured accurately and in the right context. Shorter or less continuous monitoring can misclassify burden, and different devices and AI algorithms do not perform identically. Wearables like watches were viewed as useful complements, especially for broad screening and patient engagement, but not yet replacements for clinical-grade continuous monitors.<br /><br />AI and automated interpretation were seen as promising but still needing physician overread, validation, and post-market surveillance. The panel also called for better standardization, more accessible monitoring, improved data workflows, and stronger integration of new sensors—especially accelerometers, oxygen saturation, and potentially other signals—to expand monitoring beyond AF and into broader cardiovascular risk detection.

Keywords

atrial fibrillation

AF ablation

cardiac monitoring

AF burden

wearable devices

artificial intelligence

anticoagulation

symptom assessment